Published on February 10, 2011
Exhibit
99.1
NEOGENOMICS,
INC.
PRESS
RELEASE
FOR
IMMEDIATE RELEASE
NeoGenomics
Announces Changes to its Board of Directors
Ft. Myers, Florida – February 10,
2011 - NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of
cancer-focused genetic testing services announced today that Kevin
C. Johnson and Raymond R. Hipp have joined its Board of
Directors. Mr. Johnson’s appointment was effective October 28, 2010
and filled the vacancy created by the resignation of Mr. George
O’Leary. Mr. Hipp’s appointment was effective as of February 3,
2011 and filled the vacancy created by the resignation of Dr. Marvin
Jaffe.
Mr.
Johnson is Chairman of the Board of Aureon Biosciences, Inc. a medical
technology company focused on determining likely paths for patients’
cancers. He also serves on the Board of Precision Therapeutics, a
diagnostics services company using a proprietary tumor cell-based platform to
measure patient's tumor sensitivity and resistance to a range of therapeutic
alternatives under consideration. From May 1996 until January 2003,
Mr. Johnson was Chairman, Chief Executive Officer and President of DIANON
Systems, Inc., a publicly-traded cancer diagnostic services company providing
anatomic pathology and molecular genetic testing services to physicians
nationwide. During that time, DIANON grew annual revenues from
approximately $56 million in 1996 to approximately $200 million in 2002, and
DIANON’s market capitalization grew from $45 million to approximately $600
million when it was sold to Laboratory Corporation of America
(NYSE: LH) in January of 2003. Prior to joining
DIANON in 1996, Mr. Johnson was employed by Quest Diagnostics and Quest’s
predecessor, the Life Sciences Division of Corning, Incorporated, for 18 years,
and held numerous management and executive level positions.
Mr. Hipp
is a retired senior executive that has been involved in consulting work over the
last few years involving mergers and acquisitions as well as being a member of a
number of public company boards of directors. From July
1998 until his retirement in June 2002, Mr. Hipp served as Chairman, President
and CEO of Alternative Resources Corporation, a provider of information
technology outsourcing services. From August 1996 until May 1998, Mr.
Hipp was the Chief Executive Officer of ITI Marketing Services, a provider of
marketing services. Prior to that, Mr. Hipp held senior executive
positions with several other firms. Mr. Hipp has a B.S. from
Southeast Missouri State University. Mr. Hipp is a director and
serves on the audit committee for Gardner Denver, Inc. (NYSE: GDI), an
industrial manufacturing company. Mr. Hipp will also serve as our
Audit Committee chairperson.
1
Douglas
VanOort, Chairman and Chief Executive Officer, stated, “We are delighted to
welcome Kevin Johnson and Ray Hipp to our Board. Each of them brings
a breadth of experience and valuable perspective to NeoGenomics as we meet the
challenges and pursue the exciting opportunities ahead. We are very
pleased to have them join our team. We would also like to
recognize the many years of outstanding service that both Mr. O’Leary and Dr.
Jaffe brought to our Board. Mr. O’Leary served as a consultant and
director for a six year period during which the company experienced rapid
growth. Dr. Jaffe served as a Director since 2007 and provided
thoughtful counsel and keen medical insight. We are deeply
appreciative for their service as members of our Board of
Directors.”
About
NeoGenomics, Inc.
NeoGenomics,
Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in
cancer genetics diagnostic testing, the fastest growing segment of the
laboratory industry. The company’s testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
morphology studies, anatomic pathology and molecular genetic
testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists,
oncologists, urologists, and hospitals throughout the United States. For
additional information about NeoGenomics, visit http://www.neogenomics.com.
For more
news and information on NeoGenomics, interested parties can also access
additional investor relations material, including an investment profile and an
equity research report, from Hawk Associates at http://www.hawkassociates.com
or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.
Forward
Looking Statements
Except for
historical information, all of the statements, expectations and assumptions
contained in the foregoing are forward-looking statements. These forward
looking statements involve a
number of risks and uncertainties that could cause actual future results to
differ materially from those anticipated in the forward looking
statements, Actual results could differ materially from such statements
expressed or implied herein. Factors that might cause such a difference include,
among others, the company’s ability to continue gaining new customers, offer new
types of tests, and otherwise implement its business plan. As a result, this
press release should be read in conjunction with the company's periodic filings
with the SEC.
For
further information, please contact:
|
NeoGenomics,
Inc.
|
Hawk
Associates, Inc.
|
|
Steven
C. Jones
|
Ms.
Julie Marshall
|
|
Director
of Investor Relations
|
President
|
|
(239)
325-2001
|
(305)-451-1888
|
|
sjones@neogenomics.com
|
neogenomics@hawkassociates.com
|
2